GridAI Technologies Corp., formerly known as Entero Therapeutics, Inc., reported a significant transformation in its business model and financial performance in its latest 10-K filing for the fiscal year ending December 31, 2025. The company, which shifted its focus from biopharmaceuticals to energy technology, generated approximately $36.3 million in revenue, marking a notable increase from zero revenue in the previous year. This revenue primarily stems from the acquisition of Grid AI Corp. on September 30, 2025, which has since been consolidated into the company's financials.
The company experienced a net loss of approximately $6.6 million for the year, a substantial improvement compared to a net loss of $18.1 million in 2024. This reduction in losses was attributed to a decrease in general and administrative expenses, which fell by 62.6% to about $5.5 million, largely due to the absence of significant transaction-related costs that had impacted the previous year. Research and development expenses remained relatively stable, totaling approximately $925,000, reflecting ongoing activities related to the company's legacy biopharmaceutical program, Adrulipase.
Strategically, the acquisition of Grid AI Corp. has allowed GridAI to pivot towards developing software solutions for energy orchestration and optimization, particularly targeting AI data centers and large energy users. The company is currently in the development stage of its AI data center platform, which aims to optimize distributed energy resources. However, as of the end of 2025, no major customers had been secured, and the company is focusing on building its commercial pipeline through consulting engagements and targeted business development initiatives.
Operationally, GridAI Technologies has undergone significant changes, including a reduction in headcount to manage cash burn and a strategic pivot towards energy technology. The company is also navigating compliance with Nasdaq listing requirements, having received multiple notices regarding its compliance status throughout 2025. As of April 2026, the company was notified of a failure to timely file its annual report, which could impact its listing status. Looking ahead, the company acknowledges the need for additional capital to support its operations and strategic initiatives, raising concerns about its ability to continue as a going concern without securing further funding.
In summary, GridAI Technologies Corp. is in a transitional phase, moving from a clinical-stage biopharmaceutical company to a technology-driven energy solutions provider. While the company has made strides in revenue generation and reduced its losses, it faces challenges in customer acquisition, compliance, and securing necessary funding for future growth.
About GridAI Technologies Corp.
Entero Therapeutics, Inc. develops targeted, non-systemic therapies for gastrointestinal diseases, focusing on locally acting biologics like Adrulipase for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis. The company advances its products through clinical trials, leveraging proprietary enzymes and formulations, and operates in regulated markets worldwide. It emphasizes innovative drug delivery, intellectual property protection, and strategic collaborations within the biopharmaceutical industry.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov